Caribou Biosciences

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alignment Healthcare

The market has already risen sharply this year, but Wall Street analysts think these two stocks haven't received the attention they deserve. Caribou Biosciences is a clinical-stage drugmaker developing one-size-fits-all cellular cancer therapies.

2 Growth Stocks That Could Rocket 81% to 233% Higher, According to Wall Street

Caribou Biosciences, Inc. (CRBU) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, CRBU broke through the 200-day moving average, which suggests a long-term bullish trend.

Caribou Biosciences, Inc. (CRBU) Just Overtook the 200-Day Moving Average

AT&T

Sudden and dramatic downturns in a company's share price can sometimes represent an incredible buying opportunity. Caribou Biosciences and AT&T may fall into this bucket after losing a significant chunk of their value in recent trading sessions.

2 Stocks I'm Buying on the Dip This Week

Caribou Biosciences' results from the dose expansion portion of the phase 1 ANTLER study, using CB-010 for the treatment of patients with relapsed/refractory second-line LBCL patients, are expected in the 1st half of 2024. A $25 million equity investment from Pfizer was achieved. Dose escalation updates to be released from ongoing open-label phase 1 CaMMouflage study as it progresses; This study is using CB-011 for the treatment of patients with r/r MM.

Caribou Biosciences: Positive CB-010 Data Leads To First Half 2024 Catalyst

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 19,230,769 shares of its common stock at a public offering price of $6.50 per share. All of the common stock to be sold in the offering will be offered by Caribou. The gross proceeds to Caribou from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125 million, excluding any exercise of the underwriters' option. Caribou has granted the underwriters a 30-day option to purchase up to an additional 2,884,615 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.

Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering

Shares of Caribou Biosciences Inc. CRBU, +4.90% tumbled 9.7% after hours on Thursday after the biopharma company said it had begun a $100 million share offering. The company, which focuses on genome editing, said it would grant the underwriters a 30-day option to buy up to an extra $15 million in shares at the public offering price.

Caribou Biosciences offers more stock, and shares fall

Caribou Biosciences Inc said on Thursday its experimental CAR T-cell therapy helped clear all signs or decrease tumor size in 94% of patients being treated for a type of cancer in the lymph nodes in a small, early-stage trial.

Caribou's cell therapy shows promise in early-stage cancer study

BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has commenced an underwritten public offering of $100 million of shares of its common stock. Caribou intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the proposed offering will be offered by Caribou. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering.

Caribou Biosciences Announces Proposed Public Offering of Common Stock

-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR) rate, and 44% CR rate at ≥6 months following a single dose of CB-010; 24 months is the longest CR maintained to date --

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

CRISPR Therapeutics

Gene editing holds the potential to disrupt the standard of care for scores of devastating human ailments. Caribou Biosciences and CRISPR Therapeutics are two names at the forefront of this emerging field.

2 Magnificient Growth Stocks to Buy in July

Here is how Caribou Biosciences, Inc. (CRBU) and Edwards Lifesciences (EW) have performed compared to their sector so far this year.

Is Caribou Biosciences (CRBU) Outperforming Other Medical Stocks This Year?

The mean of analysts' price targets for Caribou Biosciences, Inc. (CRBU) points to a 316.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Caribou Biosciences, Inc. (CRBU)? Wall Street Analysts Think 316.72%

Pfizer

Shares of Caribou Biosciences NASDAQ: CRBU were up 45% yesterday after Pfizer NYSE: PFE made a $25 million equity investment. On Thursday, the company said Pfizer bought almost 4.7 million shares of CRBU on June 29 at $5.33 a share.

Pfizer Just Invested $25 million In This Biotech

Caribou Biosciences (CRBU) gets a major boost with a $25 million equity investment by Pfizer, which will accelerate the development of its allogeneic CAR-T cell therapy pipeline.

Caribou Biosciences (CRBU) Soars on $25M Investment by Pfizer

Caribou Biosciences, Inc. (CRBU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Caribou Biosciences, Inc. (CRBU) Surges 45.6%: Is This an Indication of Further Gains?

Affirm

Here are three of today's notable movers, as the  broader market  takes a tumble following this morning's flood of economic data.

3 Stocks Moving Today: CRBU, META, AFRM

Caribou is a clinical-stage biotech that specializes in CRISPR gene-editing therapies. Caribou said it had $291 million in cash at the end of the first quarter.

Why Shares of Caribou Biosciences Are Skyrocketing Today

Caribou Biosciences (NASDAQ: CRBU ) stock is taking off on Thursday after the gene-editing company announced an investment from Pfizer (NYSE: PFE ). Caribou Biosciences reports that Pfizer has made a $25 million equity investment in the company.

The $25 Million Reason Caribou Biosciences (CRBU) Stock Is Soaring Today

Pfizer has invested $25 million to buy a minority stake in Caribou Biosciences , making it the latest small biotechnology firm to attract the pharmaceutical giant's interest.

Pfizer makes equity investment in Caribou Biosciences

Shares of Caribou Biosciences Inc. CRBU ran up 21.3% toward a three-month high in premarket trading Thursday, after the genome-editing biopharmaceutical company said drug giant Pfizer Inc. has made a $25 million equity investment in the company. Pfizer shares slipped 0.1% ahead of the open.

Caribou Biosciences stock soars after Pfizer buys stock priced at a 31% premium

-- Pfizer purchases $25 million of Caribou common shares -- -- Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfizer Global Product Development, has joined Caribou's Scientific Advisory Board --

Caribou Biosciences Announces $25 Million Equity Investment from Pfizer

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Caribou Biosciences, Inc. (NASDAQ: CRBU) on behalf of long-term stockholders following a class action complaint that was filed against Caribou on April 11, 2023 with a Class Period from July 23, 2021 to December 9, 2022, or pursuant to the Company's July 2021 IPO. Our investigation concerns whether the board of directors of Caribou have breac.

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.35 per share a year ago.

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Lags Revenue Estimates

-- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients at dose level 1 --

Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

-- Dr. Schuster is a world-renowned hematologist and pioneer in  CAR-T cell therapy development -- BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Stephen J. Schuster, MD, to its scientific advisory board (SAB). Dr. Schuster is an expert in treating patients with lymphoma and developing novel treatments, including pioneering the development of chimeric antigen receptor (CAR)-T cell therapies.

News for Caribou Biosciences Stock (CRBU)